Hypertrophic Cardiomyopathy

Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic Cardiomyopathy

By MedXY 12/25/2025

The MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology news

VO2T12.5% Emerges as a Key Physiological Marker for Cardiac Performance and Treatment Efficacy in Obstructive HCM

By MedXY 12/24/2025

A substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel, clinically relevant CPET metric that correlates with cardiac hemodynamics, predicts heart failure outcomes, and improves significantly with aficamten treatment in patients with obstructive hypertrophic cardiomyopathy.

Cardiology news

Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial

By MedXY 12/24/2025

While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesting a potent biological effect on myocardial wall stress and chronic injury.

Cardiology news

Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM

By MedXY 12/24/2025

This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offering a simple yet powerful tool for clinical cardiopulmonary exercise testing.

Cardiology news Specialties

High Prevalence and Clinical Impact of Sleep Apnea in Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort Study

By MedXY 09/27/2025

Sleep disordered breathing affects over half of patients with hypertrophic cardiomyopathy, correlating with worsening myocardial remodeling, diastolic dysfunction, and subclinical myocardial injury, underscoring the need for clinical trials on intervention.

Cardiology Specialties

Unveiling the Genetic Complexity of Hypertrophic Cardiomyopathy: The Impact of Intermediate Effect Variants

By MedXY 09/07/2025

Intermediate effect genetic variants contribute significantly to hypertrophic cardiomyopathy risk and modify disease severity and outcomes, especially when coexisting with monogenic mutations.

Cardiology news Pathology & Lab Medicine Specialties

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

By MedXY 09/05/2025

This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the SEQUOIA-HCM trial.

Cardiology news Specialties

Long-Term Benefits and Safety of Mavacamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the VALOR-HCM 128-Week Study

By MedXY 08/17/2025

The VALOR-HCM trial demonstrates that mavacamten sustains symptomatic improvement and significantly reduces septal reduction therapy (SRT) need over 128 weeks in severely symptomatic obstructive hypertrophic cardiomyopathy patients.